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Beta-carotene supplementation in smokers reduces the frequency of
micronuclei in sputum
G. van Poppel, F.J. Kok & R.J.J. Hermus
TNO Toxicology and Nutrition Institute, PO Box 360, 3700 AJ Zeist, The Netherlands.
Summary P-carotene has been hypothesised to reduce lung cancer risk. We studied the effect of 14 weeks of
P-carotene supplementation (20 mg d-1) on the frequency of micronuclei in sputum in 114 heavy smokers in a
double-blind trial. Micronuclei reflect DNA damage in exfoliated cells and may thus provide a marker of
early-stage carcinogenesis.
Pre-treatment blood levels of cotinine, P-carotene, retinol and vitamins C and E were similar in the placebo
group (n = 61) and the treatment group (n = 53). Plasma 1-carotene levels increased 13-fold in the treatment
group during intervention. Initial micronuclei counts (per 3,000 cells) were higher in the treatment group than
in the placebo group (5.0 vs 4.0, P<0.05). During intervention, the treatment group showed a 47% decrease,
whereas the placebo group showed a non-significant decrease (16%). After adjustment for the initial levels, the
treatment group had 27% lower micronuclei counts than the placebo group at the end of the trial (95% CI:
9-41%).
These results indicate that P-carotene may reduce lung cancer risk in man by preventing DNA damage in
early-stage carcinogenesis.
The scientific interest in the role of carotenoids and retinoids
in the prevention of human cancer has culminated in recent
years (Editorial, 1991; Meyskens, 1990). Especially for lung
cancer, epidemiological studies have consistently shown in-
verse associations between plasma or dietary P-carotene and
cancer incidence (Willett & MacMahon, 1984; Colditz et al.,
1987; Fontham, 1990). Since these studies cannot prove
causal associations, two large randomised trials are currently
conducted to evaluate the beneficial effect of P-carotene on
human cancer development (Hennekens & Eberlein, 1985;
Albanes et al., 1986). These intervention studies, however,
provide little information on biological mechanisms.
Damage to DNA is considered a crucial mechanism in
cancer development (Weinstein, 1988). Micronuclei, DNA
fragments in exfoliated cells, may thus provide a marker of
early-stage carcinogenesis in target tissues (Lippman et al.,
1990a,b; Stich et al., 1984a). In cigarette smokers, elevated
micronuclei counts in expectorated sputum (Fontham et al.,
1986) or bronchial brushings (Lippman et al., 1990a) are
thought to reflect increased lung cancer risk.
So far, no studies have investigated the effect ofP-carotene
supplementation on sputum micronuclei, as a reflection of
lung cancer risk. P-Carotene has been shown to reduce mic-
ronucleated buccal mucosal cells in tobacco chewers (Stich et
al., 1984a, 1985, 1988) and may thus reduce risk for oral
cancer. These trials, however, did not measure plasma levels
of P-carotene and retinol. Moreover, other antioxidant
vitamins may modify the effects of P-carotene (Meyskens,
1990). We now report on a 14-week, double-blind, ran-
domised placebo-controlled trial of the effect of P-carotene
on sputum micronuclei in 114 heavy smokers. We measured
plasma cotinine as a marker for tobacco exposure and
monitored blood levels of P-carotene, retinol and the antiox-
idant vitamins C and E.
Subjects and methods
Study design
Healthy male employees of the AMEV Insurance Company,
the Taxation Office and the Power Company at Utrecht,
Netherlands, were asked to volunteer for the intervention
trial, which was approved by an External Review Board for
experiments with human volunteers. All participants had
smoked at least 15 cigarettes per day for over 2 years, did
not use preparations containing retinol or carotenoids, and
did not report exposure to chemicals during working or
leisure time. The volunteers were prestratified by age, dura-
tion and quantity of smoking and randomly assigned to
either P-carotene (20 mg capsules, F. Hoffmann-La Roche) or
placebo treatment.
Blood and sputum samples were collected before and after
the 14-week treatment. The participants were instructed to
take capsules daily with the evening meal, two capsules per
day during the first 2 weeks, followed by one capsule per day
over the next 12 weeks. Every 4 weeks, the participants were
sent their next strip of 28 capsules, and were asked to return
the used strips with the capsules not taken to monitor com-
pliance. In addition, P-carotene was determined in a blood
sample taken after 7 weeks of treatment.
Initially, 163 smokers volunteered to participate; 83 were
assigned to placebo treatment, 80 to P-carotene treatment.
During the trial, a total of 13 smokers (six placebo, seven
P-carotene) discontinued participation because of stopping
smoking (n = 4), illness or an accident (n = 3), personal cir-
cumstances (n = 1), forgetting to take capsules (n = 2), or
without giving a reason (n = 3). Of the 150 smokers who
completed the trial, 29 (13 placebo, 16 13-carotene) failed to
produce sputum samples. In addition, insufficient cells could
be evaluated in seven subjects (three placebo, four P-caro-
tene), leaving 114 subjects (61 placebo, 53 P-carotene) for
data analysis.
Micronuclei in sputum
Sputum was collected and processed as described in detail by
Saccomano et al. (1978). Each participant received a careful
individual instruction on how to produce a specimen from
'deep in the lungs'. Sputum was collected at home on three
consecutive mornings, directly after rising and after carefully
rinsing the mouth. The three, or minimally two samples
collected in preservative (50 ml 50% ethanol with 2% poly-
ethylene glycol (Carbowax 1540, Merck)) were mixed, homo-
genised, centrifuged and smeared onto slides. The slides were
stained with Feulgen and fast green, which is specific for
DNA and strongly highlights micronuclei (Bruck, 1981).
For each subject, 3,000 cells were examined and evaluated
on the basis of the following criteria: shape and size typical
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of epithelial cells, a well defined nucleus and a clearly defined
cytoplasm. The criteria in defining a micronucleus were:
chromatin structure and colour intensity similar to those of
the main nucleus; on focusing, the micronucleus must be on
the same level as the nucleus, must be roundish and clearly
included in the cytoplasm. The dimensions should be less
than 1/5 of that of the main nucleus, and it should not be
connected to it. Slides were screened at 400 x magnification
and micronucleated cells were examined at 1000 x
magnification. Slides were read coded/blinded by a single
observer to exclude between-observer variation. Repeated
blinded scoring of nine samples yielded a good correlation
(Pearson r = 0.86), with two of the nine samples showing a
difference of more than one micronucleus upon rescoring.
Bloodparameters
Directly after venapuncture, non-fasting blood samples con-
taining NaEDTA as anti-coagulant were stored overnight in
the dark at 4°C for 20-23 h. Directly after opening the
evacuated tubes, the sum of L-ascorbic acid + dehydro-L-
ascorbic acid (vitamin C) was assessed in wholeblood by
HPLC with fluorometric detection (Speek et al., 1984). All-
trans retinol, a-tocopherol, P-carotene and total carotenoids
were assayed in plasma (stored at - 80°C) by HPLC with
colorimetric detection (van Vliet et al., 1991). Plasma cotinine
levels were determined by gas chromatography (Feyerabend
et al., 1984).
Data analysis
Initial baseline values and changes in these values during the
intervention period were compared between the placebo
group and the P-carotene group using the unpaired Student's
t-test. Univariate log-linear Poisson regression was used to
compare micronuclei counts between both groups, and to
evaluate associations between micronuclei counts and other
parameters. Percentual changes in micronuclei counts during
the intervention trial were quantified by analysing the final/
initial micronuclei counts ratio in binomial regression. Multi-
ple Poisson regression was used to quantify the difference in
micronuclei between the placebo and P-carotene groups after
correction for incomplete randomisation. All data analysis
were performed using the BMDP and GENSTAT packages
(Dixon, 1988; GENSTAT 5 Committee, 1987).
Results
Table I shows that the placebo and 13-carotene groups are
comparable for all characteristics and that, except for plasma
P-carotene, only minor changes occurred during the interven-
tion trial. In accordance with the stable cotinine levels, only
one smoker (placebo group) reported to have changed his
smoking habits during the trial. His plasma cotinine levels,
however, hardly changed (349 and 313 nmol ml- respec-
tively). The mean body mass index (BMI) was similar in the
placebo group (24.3 ± 3.0 kg m-2) and the P-carotene group
(24.7 ± 3.3 kg m-2), and all participants but one reported
stable weights during the trial (in one placebo participant
BMI decreased from 24.9 ± 22.2 kgm2). Reported alcohol
consumption was also similar in the placebo (13.4 g d-1) and
the P-carotene group (12.6 g d-'). After 7 weeks, mean plas-
ma P-carotene had increased 13-fold to 4.13 ± 1.79 1.mol 1'
in the supplemented group (0.26 ± 0.15 fmol- 1 in the pla-
cebo group), and remained stable up to the end of the trial.
The minimum increase in plasma P-carotene after supplemen-
tation was 1.7 fold (0.44 -* 0.74pmol 1'), and all but four
supplemented subjects had after treatment plasma levels
above 1.0 jlmol 1'. Thirteen participants (12 P-carotene and,
surprisingly, one placebo) reported to have observed skin
yellowing during the trial, whereas one of the investigators,
unaware of intervention status, noted 19 cases of skin yellow-
ing (all P-carotene subjects). Pill counts showed that 92% of
all capsules were taken (data for 103 subjects); all but four
participants took more than 75% of their capsules.
At baseline, the micronuclei counts were significantly high-
er in the 13-carotene group than in the placebo group (Figure
1 and Table II). After the intervention, however, the mic-
ronuclei counts were significantly lower in the P-carotene
group (Table II). The P-carotene group thus showed a strong
decrease in micronuclei counts, whereas the placebo group
showed a minor, non-significant decrease (Figure 2 and Table
II). In the treatment group the decrease in micronuclei was
similar (47%) in subjects with final P-carotene levels above
and below the median of 4.1 timol 1'. To obtain an unbiased
estimate of the intervention effect, we calculated the
difference between the placebo group and the 13-carotene
groups after intervention, allowing for the differences that
existed between both groups before the intervention. After
adjustment for initial micronuclei counts, the final micro-
nuclei counts were estimated to be 27% lower in the P-
carotene group than in the placebo group (95% CI:
9%-41%). Adjustment for the baseline characteristics given
in Table I did not alter this estimate, since no associations
were detected between micronuclei counts at baseline and any
of the baseline characteristics listed in Table I, or alcohol
consumption (All Pearson r<0.14).
The micronuclei counts before and after the trial were
clearly associated (P<0.001), but we observed only a modest
correlation in both the placebo group (Pearson r = 0.29) and
the P-carotene group (Pearson r = 0.40). The micronuclei
counts thus show a large within-person variation (see also
Figure 2).
Discussion
This trial in heavy smokers shows a reduction in frequency of
micronucleated sputum cells after supplementation with P-
carotene, suggesting that the inverse epidemiological associa-
tion between P-carotene and lung cancer (Willett & Mac-
Mahon, 1984; Colditz et al., 1987; Fontham, 1990) is indeed
due to 13-carotene, and not to associated food or life-style
Table I Baseline characteristics (mean ± s.d.) and changes in these characteristics during a 14-week
intervention trial in male smokers, assigned to either P-carotene or placebo treatment
Placebo group (n = 61) P-carotene group (n = 53)
Baseline Change Baseline Change
values (after-before) values (after-before)
Age (yrs) 40.0± 10.1 n.a. 40.2 ± 9.1 n.a.
Number of cigarettes per day 20.8 ± 6.7 n.a. 21.7 ± 6.4 n.a.
Years of smoking 21.9 10.5 n.a. 22.0 ± 9.1 n.a.
Blood vitamin C qLmol ') 37.6 18.8 - 0.4± 16.7 38.2 ± 17.2 - 1.1 ± 16.0
Plasma retinol (Jumol 1-) 2.33 ± 0.60 - 0.06 ± 0.42 2.38 ± 0.55 - 0.01 ± 0.41
Plasma a-tocopherol (,umol I') 30.5± 7.1 1.4 ± 4.3 31.2 ± 7.0 0.5 ± 3.2
Plasma P-carotene (jmol 1-) 0.28 ± 0.18 - 0.02 ± 0.13 0.32 ± 0.16 3.79 ± 2.02a
Plasma total carotenoids (Jrmol 1) 1.56 ± 0.59 0.09 ± 0.43 1.49 ± 0.58 3.66 ± 1.93a
Plasma cotinine (ngml-') 323.1 ± 122.6 - 8.4 ± 72.8 332.8 ± 109.6 - 8.0 ± 74.1
aP-carotene group significantly different from the placebo group, P<0.0001. n.a. =not applicable.1166 G. VAN POPPEL et al.
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Figure 1 Distribution of micronuclei-counts at the start of a 14-week trial in male smokers, assigned to either placebo (n = 61) or
P-carotene (n = 53) treatment.
Table II Micronuclei counts (mean per 3,000 cells + s.d.) and
changes in micronuclei counts during a 14-week intervention trial in
male smokers, assigned to either P-carotene or placebo treatment
Placebo group P-carotene group
(n=61) (n= 53)
Micronuclei at baselinea 4.0 + 3.5 5.0 ± 3.4
Micronuclei after 3.4 3.3 2.6 2.8
14 weeks treatmenta
Change in micronuclei - 0.6 ± 4.0 - 2.3 + 3.4
(after-before)y
% Change in micronuclei - 16 - 47
(95% confidence interval) (-31%- + 1%) (- 57%- - 35%)
ap-carotene group significantly different from placebo group;
P<0.05.
factors. These results thus support a protective role for 1-
carotene in the development of human cancer, as proposed
by Peto et al. (1981). Moreover, the results indicate that
,B-carotene is protective in man by preventing DNA damage
in target tissues, thus providing a plausible mechanism of
action.
The approximately 30% reduction in micronuclei after
P-carotene treatment is in accordance with the effect of P-
carotene reported in buccal mucosa of betel nut chewers
(Stich et al., 1984a) and tobacco chewers (Stich et al., 1985,
1988). Our findings extend these observations to cigarette
smoke-induced tracheobronchial micronuclei, which may
reflect lung cancer risk (Stich & Rosin, 1984b; Lippman et
al., 1990a,b). Moreover, as plasma retinol levels were not
changed, this study shows that the provitamin P-carotene
does not exert its action after intestinal or hepatic conversion
to retinol. It thus seems that P-carotene per se is effective at
the cellular level. The protective action of P-carotene may be
explained by its anti-oxidant capacity to quench highly reac-
tive singlet oxygen and free radical species (Krinsky, 1989).
Free radicals are abundant in cigarette smoke and tar (Pryor
et al., 1983) and are believed to initiate cancer by damaging
DNA (Pryor, 1987). In addition, P-carotene has been hypo-
thesised to be effective after conversion to retinol at a tissue
or cellular level (de Vet, 1989). P-carotene could thus rapidly
compensate for local deficiencies in retinol, which may be
induced by carcinogens (Edes et al., 1991).
Micronuclei in exfoliated epithelial cells reflect the extent
ofchromosome breakage due to carcinogenic exposure, when
the cells were dividing a few days or weeks earlier, in the
basal layer of the epithelium of the tracheobronchial tree
(Stich & Rosin, 1984b). As DNA damage is considered
crucial in carcinogenesis (Weinstein, 1988), the frequency of
micronuclei may thus reflect cancer risk. In several experi-
mental models, including the rat bronchial carcinoma model
(Stich & Rosinn, 1984b; Lippman et al., 1990b), high fre-
quencies of micronuclei are observed after carcinogen expo-
sure. In man, numbers of micronuclei in buccal mucosa cells
have been found to increase after exposure to tobacco and
alcohol (Stich & Rosin, 1983a), betel quid (Stich et al., 1982)
and X-radiation (Stich et al., 1983b); all these exposures are
known causes of oral cancer. Similarly, smokers have ele-
vated frequencies of micronucleated cells in expectorated
sputum (Fontham, 1990) and bronchial brushings (Lippman
et al., 1990a). These observations strongly suggest that mic-
ronuclei indeed reflect early or intermediate stages of the
carcinogenic process. Follow-up studies on the predictive
value of micronuclei for cancer development, however, have
not been published.
Surprisingly, our data show higher initial micronuclei
counts in the P-carotene group, indicating unsuccessful ran-
domisation. The number of inevaluable volunteers, as well as
the reasons for inevaluability were similar in the placebo and
the P-carotene groups, and can therefore not explain this
difference. During the trial, the P-carotene and placebo
groups were equally represented in all staining and scoring
runs, so that any systematic difference in staining or scoring
procedures between the two groups seems improbable. More-
over, all slides were coded, and scored by a single technician,
and all other baseline characteristics measured (Table I) were
comparable between the two groups. Regression to the mean
may have influenced the observed reduction in the P-carotene
group, but cannot have influenced after-treatment micro-BETA-CAROTENE AND MICRONUCLEI IN SPUTUM OF SMOKERS 1167
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Figure 2 Changes in micronuclei-counts during a 14-week trial in male smokers, assigned to either placebo (n = 61) or P-carotene
(n = 53) treatment.
nuclei counts. Despite the higher initial count, the after
treatment counts were significantly lower in the P-carotene
group, even without adjustment for initial counts.
In the treatment group, we did not observe a dose-
response relationship between plasma P-carotene and reduc-
tion in micronuclei count. However, we evaluated the effect
of only one high dose of P-carotene, and almost all subjects
showed dramatic increases in plasma levels. Furthermore, the
limited number of subjects, the low frequency of micronuclei,
as well as the considerable within-person variation in mic-
ronuclei counts make it difficult to evaluate a dose-response
relationship. The low frequency of micronuclei in this study
may be partly due to our stringent scoring criteria, aimed at
identifying micronuclei reproducibly and with a high cer-
tainty. The large within-person variability may be explained
by an inherent variability in sampling site, as expectorated
cells may originate from all sites in the tracheobronchial tree.
This large random sampling variation implies that the statis-
tical power of studies using sputum is only sufficient to
demonstrate large effects in study groups ofconsiderable size.
For future studies, repeated sampling and scoring can be
used to diminish within-person variation. In addition, a run-
in period prior to treatment could be used to assess eligibility
with respect to sputum production and to stratify the treat-
ment groups on micronuclei counts. Alternatively, studies
using bronchial brushings, though more invasive, have the
merit of being site-specific and may prove more useful to
evaluate smaller effects, such as dose responses. Such studies
may also be used to evaluate variations in counts between
different sites. In addition, cellular levels of P-carotene could
be studied in future studies, since plasma P-carotene levels
may not wholly reflect tissue levels of P-carotene in the
tracheobroncheal tree.
Our data suggest that P-carotene is effective by preventing
DNA damage and may thus affect early or intermediate
stages of carcinogenesis. This is in line with laboratory
studies that indicate a role of P-carotene in antimutagenesis
and prevention of malignant transformation (Krinsky, 1989).
However, there are also indications that P-carotene may
affect later stages of carcinogenesis (Prabhala et al., 1991).
The recently reported lack of effect of P-carotene in trials on
cervical dysplasia (de Vet et al., 1991) and second skin
cancers (Greenberg et al., 1990) may, apart from site
specificity, be explained if P-carotene is primarily effective in
earlier stages of carcinogenesis. To address this question, the
ongoing intervention studies in cancer incidence will need a
long follow-up. Indeed, the P-carotene trial in the Physicians
Health Study has recently been extended to cover more than
10 years follow-up (Manson et al., 1991).
This study yields evidence that the observed inverse asso-
ciation between P-carotene and lung cancer is due to P-
carotene per se. Though the predictive value of micronuclei
for cancer risk remains to be shown definitively, our results
suggest that P-carotene may indeed reduce human cancer
risk. It is clear that the health benefits of stopping smoking
will far outweigh those of dietary changes (Colditz et al.,
1987). These results should therefore not be explained as a
way to prevent lung cancer in people who continue to smoke.
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